Summary
Kappa light chains are more common in antibody therapeutics. Only ten percent of antibody therapeutics have the lambda subtype light chains, compared to 35–40% of natural antibodies; (1) determine that this is due to poor developability, including large hydrophobic patches (see Lambda light chains are more hydrophobic) and longer CDRH3 loops. This has also been attributed to the larger proportion of kappa light chains in mice (95% of all light chains).
Figures
Ref (1)
See also
1.
Raybould MIJ, Turnbull OM, Suter A, Guloglu B, Deane CM. Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling. Communications Biology. 2024;7(1). Available from: https://doi.org/10.1038/s42003-023-05744-8